insurance pays for stem cells, eh? thats news to me. im not talking about PRP, which -- although overutilized -- is at least somewhat legitimate.
claiming to be too good/pure/ethical/independent for a hospital, then blasting your patients with stems cells for cash is the height of hypocrisy.
the board of directors at a church is non-biased? LOL
so, you are OK with churches robbing us blind, but not with hospitals.
look, i agree that non-profit hospitals definitely stretch the rules. rules need to be tightened, no doubt. however, thats more regulations, which we know you hate. cant have it both ways
Yes, we have contracts with health plans for BMAC injections. But like everything else, if it is not covered by insurance we have a cash price.
I just walked out a room for a follow-up ACL BMAC injection. Progressing well in PT. Weaned from brace.
J Transl Med. 2018 Sep 3;16(1):246. doi: 10.1186/s12967-018-1623-3.
Symptomatic anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow concentrate and platelet products: a non-controlled registry study.
Centeno C1,2,
Markle J1,
Dodson E3,
Stemper I2,
Williams C1,
Hyzy M1,
Ichim T4,
Freeman M5.
Author information
Abstract
BACKGROUND:
Bone marrow concentrate (BMC) has shown promise in the treatment of several orthopedic conditions. This registry study investigated the use of autologous BMC and platelet products for percutaneous anterior cruciate ligament (ACL) treatment.
METHODS:
Twenty-nine patients presenting to a single outpatient interventional musculoskeletal and pain practice with symptomatic grade 1, 2, or 3 ACL tears with less than 1 cm retraction were enrolled. Patients were treated with a percutaneous ACL injection of autologous BMC and platelet products using fluoroscopic guidance. Pre- and post-treatment magnetic resonance imaging analysis was completed for 23 patients using ImageJ software for an objective quantitative analysis of pixel density as a proxy for ACL integrity. Subjective clinical outcome measures collected pre-treatment and at 1, 3, 6, 12, 18, 24, and 36 months post-treatment include the Numerical Pain Scale (NPS), the Lower Extremity Functional Scale (LEFS), the International Knee Documentation Committee (IKDC) form, and a modified version of the Single Assessment Numeric Evaluation.
RESULTS:
Seventy-seven percent of patients treated with BMC injections into the ACL showed significant improvement (p < 0.01) in objective measures of ACL integrity at an average of 8.8 months (median 4.7 months). The mean of last patient-reported improvement was 72% (SD = 35) at an average of 23 (SD = 10) months post-treatment. Mean scores were found to be significantly different (p < 0.05) for the NPS at 6, 18, and 24 months, and LEFS and IKDC at all time points (i.e. 1, 3, 6, 12, 18, 24, and 36 months) relative to baseline.
CONCLUSION:
In symptomatic patients with grade 1, 2, or even grade 3 tears with minimal retraction, ACL treatment with percutaneous injection of BMC and platelet products shows promise as a non-surgical alternative. However, a larger randomized controlled trial is warranted to confirm these findings. Trial registration
NCT03011398. A Clinical Registry of Orthobiologics Procedures.
Project Activate: Mindfulness and Acceptance Based Behavioral Treatment for Weight Loss - Full Text View - ClinicalTrials.govNCT03011398?term=orthobiologics&rank=1 . Registered 29 December 2016. Enrollment 1 December 2011-retrospectively registered.
KEYWORDS:
ACL; Anterior cruciate ligament; BMC; Bone marrow concentrate; Knee injury; Knee instability; MSC; Mesenchymal stem cells; Percutaneous injections; Regenerative medicine
PMID: 30176875 PMCID:
PMC6122476 DOI:
10.1186/s12967-018-1623-3
I wish you would fact check before posting.